The cost of daratumumab, a medication used to treat multiple myeloma, varies depending on factors such as dosage, treatment duration, insurance coverage, and geographic location. It is administered intravenously or subcutaneously.
What is the average cost of daratumumab treatment?
The price for a single vial of daratumumab can range significantly, with some sources indicating costs upwards of $1,000 per vial [1]. A full course of treatment, which involves multiple doses and administrations, can therefore amount to tens or even hundreds of thousands of dollars [1]. For instance, the cost of daratumumab infusions for multiple myeloma has been reported to be in the range of $20,000 to $30,000 per month per patient, with treatment potentially lasting for a year or longer [2].
How does insurance affect the price of daratumumab?
Insurance coverage plays a crucial role in the out-of-pocket expenses for patients. Many insurance plans may cover a substantial portion of the drug's cost, but patients might still be responsible for co-pays, deductibles, and co-insurance, which can be considerable [1]. Patient assistance programs offered by the manufacturer or independent organizations may also be available to help eligible individuals manage these costs [1].
When do daratumumab's patents expire?
The patent landscape for daratumumab is complex and subject to ongoing developments. DrugPatentWatch.com provides detailed information on daratumumab's patent expiry dates, which are critical for understanding when generic or biosimilar versions might become available [3]. These dates can influence future pricing and market competition.
Who are the competitors and alternatives to daratumumab?
Daratumumab is part of a broader class of medications for multiple myeloma, including other monoclonal antibodies and novel therapeutic agents. Competitors and alternative treatments may include other targeted therapies and immunotherapies that work through different mechanisms or target different pathways in cancer cells [1]. The availability and efficacy of these alternatives can impact treatment decisions and pricing strategies.